Publicacions en què col·labora amb Ramón García Sanz (151)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  3. Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient

    Biomedicines, Vol. 12, Núm. 1

  4. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

2023

  1. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  2. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    Blood Cancer Journal

  3. Characterization of the first HLA-DQA1 allele with Aspartic Acid in the transmembrane domain, HLA-DQA1*05:71

    HLA, Vol. 102, Núm. 3, pp. 381-383

  4. Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level

    Disease models & mechanisms, Vol. 16, Núm. 8

  5. Detection and characterization of the novel HLA-DPA1*02:66:02N allele, with a premature stop codon in exon 2

    Human Immunology, Vol. 84, Núm. 4, pp. 296-300

  6. Identification of the novel HLA-DQA1*01:04:07 allele with a synonymous substitution and an intronic insertion

    HLA, Vol. 101, Núm. 5, pp. 559-561

  7. Identification of two novel HLA-DQB1*03:01:01 intronic variants: HLA-DQB1*03:01:01:47 and -DQB1*03:01:01:48

    HLA, Vol. 101, Núm. 5, pp. 562-564

  8. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

  9. Multiple myeloma with t(11;14): impact of novel agents on outcome

    Blood Cancer Journal, Vol. 13, Núm. 1

  10. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

  11. The novel HLA-DQB1*03:02:01:14 allele was possibly generated by a recombination event

    HLA, Vol. 102, Núm. 2, pp. 258-260

  12. Transitions in intronic regions result in two novel HLA-DQB1 alleles: –DQB1*05:02:01:13 and -DQB1*05:02:01:14

    HLA, Vol. 102, Núm. 2, pp. 260-262

2022

  1. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  2. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  3. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  4. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871